At the 2025 Global Forum on Nicotine in Warsaw, Emplicure Chief Clinical, Regulatory & Quality Officer Dr. Anna Franzén delivered a compelling presentation during the panel “Nicotine Pouches: What’s the Real Story?”. What Dr. Franzén Shared Dr. Franzén emphasised three critical pillars for nicotine pouches: Established safety of medicinal nicotine — highlighting how regulatory frameworks for nicotine…
As novel nicotine pouches continue to gain traction across global markets, questions around their contents and safety remain top of mind for regulators, public health experts, and adult consumers. A comprehensive study published in the journal Drug and Chemical Toxicology helps answer one of the most pressing questions: What’s actually inside these tobacco-free pouches? 🧪…
As novel nicotine products evolve, so too do the molecules behind them. One of the newest and most controversial is 6-methyl nicotine (6-MN)—a synthetic analog of nicotine that has now been detected in certain vaping devices and oral pouches. This compound, structurally similar to nicotine but chemically modified with a methyl group, may increase potency…
A newly updated systematic review and meta-analysis published in F1000Research delivers one of the most comprehensive evaluations to date on the relative risks of nicotine delivery products. The findings are timely—and critical—for public health officials, regulators, and harm reduction advocates working to reshape tobacco policy for the 21st century. 🔍 Study Overview Researchers reviewed 123…
As smoking rates remain stubbornly high across much of the Middle East and North Africa (MENA), health authorities and policymakers are exploring new ways to remember duce the region’s tobacco-related disease burden. One such possibility—oral nicotine pouches—is starting to enter the conversation. A recent article from Economy Middle East raises the question: Could these smoke-free…
A new study highlighted by Medical Xpress raises important questions about the role of flavors in nicotine pouches—and how they may influence the product’s appeal and addictiveness. As nicotine pouches gain traction as smoke-free alternatives, understanding these dynamics is essential for responsible public health policy. Here’s what the research shows, and why balanced regulation—not panic—is…
A recent article by Griffith University’s Blurred Minds Academy raises concerns about nicotine pouches, suggesting that they are being marketed in a way that appeals to minors. While protecting youth is critical, this narrative misrepresents the purpose and regulatory framework surrounding these products—and risks derailing an important harm reduction strategy for adults seeking safer alternatives…
In a significant move towards tobacco harm reduction, Greece has emerged as the first European Union member state to permit scientifically substantiated claims regarding the reduced health risks of smoke-free alternatives. This progressive stance is part of Greece’s comprehensive National Action Plan Against Smoking, which emphasizes harm reduction alongside prevention, cessation support, and protection from…
The closing session of EVO NXT Milan 2025 brought together a remarkable group of experts from across the novel nicotine industry to discuss one of the most pressing questions facing the category: how can innovation thrive under increasing regulatory scrutiny? Moderated by Robert Burton (Plxsur), the session featured insights from Geir Hammer (Den Norske Snusfabrikken),…
Recent research from Duke University School of Medicine has examined the role of artificial sweeteners in oral nicotine pouches and their potential effects on user behavior. The study, which analyzed popular nicotine pouch brands such as On!, Zyn, and Velo, found that these products contain significant amounts of sweeteners like acesulfame-K and sucralose. These additives…